|
US20060222647A1
(en)
*
|
1993-05-27 |
2006-10-05 |
Beavo Joseph A |
Methods and compositions for modulating the activity of PDE5
|
|
GB9301192D0
(en)
|
1993-06-09 |
1993-06-09 |
Trott Francis W |
Flower shaped mechanised table
|
|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9423911D0
(en)
*
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9423910D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
IL126951A0
(en)
*
|
1996-05-10 |
1999-09-22 |
Icos Corp |
Carboline derivatives
|
|
GB9612514D0
(en)
*
|
1996-06-14 |
1996-08-14 |
Pfizer Ltd |
Novel process
|
|
DE19642284A1
(de)
*
|
1996-10-14 |
1998-04-16 |
Merck Patent Gmbh |
Pyrazolinone zur Behandlung von Potenzstörungen
|
|
CZ299633B6
(cs)
*
|
1997-04-25 |
2008-09-24 |
Pfizer Inc. |
Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
|
|
CA2291256A1
(en)
*
|
1997-05-29 |
1998-12-03 |
Mochida Pharmaceutical Co., Ltd. |
Therapeutic agent for erection dysfunction
|
|
US20020025969A1
(en)
*
|
1997-07-09 |
2002-02-28 |
Wolf-Georg Forssmann |
Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
|
|
US6103765A
(en)
|
1997-07-09 |
2000-08-15 |
Androsolutions, Inc. |
Methods for treating male erectile dysfunction
|
|
EP1005336A4
(en)
|
1997-07-09 |
2001-01-17 |
Androsolutions Inc |
IMPROVED METHODS AND COMPOSITIONS FOR TREATING MALE ERECTIONAL DISORDERS
|
|
US6399618B1
(en)
|
1997-07-09 |
2002-06-04 |
Cardiome Pharma Corp |
Compositions and methods for modulating sexual activity
|
|
US20030077229A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
|
|
US6593369B2
(en)
|
1997-10-20 |
2003-07-15 |
Vivus, Inc. |
Methods, compositions, and kits for enhancing female sexual desire and responsiveness
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
US6156753A
(en)
*
|
1997-10-28 |
2000-12-05 |
Vivus, Inc. |
Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
US6548490B1
(en)
|
1997-10-28 |
2003-04-15 |
Vivus, Inc. |
Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
WO1999021558A2
(en)
*
|
1997-10-28 |
1999-05-06 |
Vivus, Inc. |
Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
AU740758B2
(en)
|
1997-10-28 |
2001-11-15 |
Vivus, Inc. |
Treatment of female sexual dysfunction
|
|
US6037346A
(en)
*
|
1997-10-28 |
2000-03-14 |
Vivus, Inc. |
Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
US6127363A
(en)
*
|
1997-10-28 |
2000-10-03 |
Vivus, Inc. |
Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
US6403597B1
(en)
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
IL135462A0
(en)
|
1997-11-12 |
2001-05-20 |
Bayer Ag |
2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
|
|
DE19752952A1
(de)
|
1997-11-28 |
1999-06-02 |
Merck Patent Gmbh |
Thienopyrimidine
|
|
CZ20002199A3
(cs)
*
|
1997-12-16 |
2001-10-17 |
Pfizer Products Inc. |
Kombinace, kompozice a kity pro léčení impotence a samičí sexuální dysfunkce
|
|
TW542719B
(en)
*
|
1998-02-23 |
2003-07-21 |
Pfizer Res & Dev |
Method of treating impotence due to spinal cord injury
|
|
TR200003039T2
(tr)
|
1998-04-20 |
2001-01-22 |
Pfizer Inc. |
Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
|
|
DE19819023A1
(de)
|
1998-04-29 |
1999-11-04 |
Merck Patent Gmbh |
Thienopyrimidine
|
|
US6132753A
(en)
*
|
1998-05-01 |
2000-10-17 |
Neal R. Cutler |
Treatment of sexual dysfunction in certain patient groups
|
|
US6132757A
(en)
|
1998-05-01 |
2000-10-17 |
Neal R. Cutler |
Treatment of sexual dysfunction in certain patient groups
|
|
US6187790B1
(en)
|
1999-03-04 |
2001-02-13 |
Neal R. Cutler |
Use of cilostazol for treatment of sexual dysfunction
|
|
US6541487B1
(en)
|
1998-05-01 |
2003-04-01 |
R.T. Alamo Ventures I, Llc |
PDE III inhibitors for treating sexual dysfunction
|
|
US6110489A
(en)
*
|
1998-05-01 |
2000-08-29 |
Cutler; Neal R. |
Use of quinolines and quinolones to treat male erectile dysfunction
|
|
BR9908716A
(pt)
*
|
1998-05-01 |
2000-11-21 |
Neal R Cutler |
Tratamento de disfunção sexual em certos grupos de pacientes
|
|
US6194433B1
(en)
|
1998-10-05 |
2001-02-27 |
Neal R. Cutler |
Sexual dysfunction in females
|
|
US6426084B1
(en)
|
2000-06-19 |
2002-07-30 |
Neal R. Cutler |
Treatment of sexual dysfunction in certain patient groups
|
|
WO1999059584A1
(en)
*
|
1998-05-20 |
1999-11-25 |
Schering Corporation |
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
|
|
EP0967284A1
(en)
*
|
1998-05-28 |
1999-12-29 |
Pfizer Limited |
Phosphodiesterases
|
|
TWI223598B
(en)
*
|
1998-06-22 |
2004-11-11 |
Pfizer Ireland Pharmaceuticals |
An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
|
|
US7087240B1
(en)
|
1998-06-25 |
2006-08-08 |
Lavipharm Laboratories Inc. |
Device and method for the treatment of erectile dysfunction
|
|
DE69927154T2
(de)
|
1998-06-25 |
2006-06-29 |
Lavipharm Laboratories, Inc. |
Vorrichtung und verfahren zur behandlung von erektionsstörungen
|
|
WO2000000199A1
(en)
*
|
1998-06-26 |
2000-01-06 |
Nastech Pharmaceutical Company, Inc. |
Nasal delivery of sildenafil citrate
|
|
DE19837067A1
(de)
|
1998-08-17 |
2000-02-24 |
Bayer Ag |
Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
|
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
ES2220109T3
(es)
*
|
1998-09-04 |
2004-12-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
5-heterociclilpirazolo (4,3-d) pirimidin-7-onas para el tratamiento de la disfuncion erectil masculina.
|
|
JP2000178204A
(ja)
*
|
1998-10-05 |
2000-06-27 |
Eisai Co Ltd |
ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
|
|
CA2346350C
(en)
|
1998-10-05 |
2008-01-08 |
Eisai Co., Ltd. |
Intraoral quickly disintegrating tablets
|
|
JP2000191518A
(ja)
*
|
1998-10-19 |
2000-07-11 |
Eisai Co Ltd |
溶解性の改善された口腔内速崩壊性錠剤
|
|
GB9823101D0
(en)
*
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
GB9823102D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
GB9823103D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
UA67802C2
(uk)
*
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
|
KR100353014B1
(ko)
*
|
1998-11-11 |
2002-09-18 |
동아제약 주식회사 |
발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
|
|
RU2220145C2
(ru)
*
|
1998-11-11 |
2003-12-27 |
Донг А Фарм. Ко., Лтд. |
Производные пиразолопиримидинона для лечения импотенции и способ их получения
|
|
US6225315B1
(en)
|
1998-11-30 |
2001-05-01 |
Pfizer Inc |
Method of treating nitrate-induced tolerance
|
|
GB9828340D0
(en)
*
|
1998-12-22 |
1999-02-17 |
Novartis Ag |
Organic compounds
|
|
US6455564B1
(en)
|
1999-01-06 |
2002-09-24 |
Pharmacia & Upjohn Company |
Method of treating sexual disturbances
|
|
WO2000043012A1
(en)
*
|
1999-01-22 |
2000-07-27 |
Selectus Pharmaceuticals, Inc. |
Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence
|
|
WO2000053148A2
(en)
*
|
1999-03-08 |
2000-09-14 |
Merck & Co., Inc. |
Methods and compositions for treating erectile dysfunction
|
|
AU765128B2
(en)
|
1999-03-22 |
2003-09-11 |
Bristol-Myers Squibb Company |
Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
|
|
US6214849B1
(en)
|
1999-04-29 |
2001-04-10 |
Lupin Laboratories Limited |
Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
|
|
US6451807B1
(en)
*
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
MXPA00003997A
(es)
*
|
1999-04-30 |
2002-03-08 |
Lilly Icos Llc |
Articulos de fabricacion.
|
|
US7258850B2
(en)
*
|
1999-05-04 |
2007-08-21 |
Aradigm Corporation |
Methods and compositions for treating erectile dysfunction
|
|
JP3145364B2
(ja)
|
1999-06-04 |
2001-03-12 |
ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド |
新規化合物及び該化合物を含有する医薬組成物
|
|
WO2000078760A1
(en)
*
|
1999-06-21 |
2000-12-28 |
The Biochemical Pharmaceutical Factory Of Zhuhai Sez |
Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine
|
|
US6303135B1
(en)
|
1999-07-08 |
2001-10-16 |
Neal R. Cutler |
Use of quinolines and quinolones to treat male erectile dysfunction
|
|
CN1077108C
(zh)
*
|
1999-07-13 |
2002-01-02 |
成都地奥制药集团有限公司 |
用于制备药物昔多芬的前体化合物
|
|
IL130968A
(en)
*
|
1999-07-15 |
2002-12-01 |
Shmuel Simon |
Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
DE19944161A1
(de)
*
|
1999-09-15 |
2001-03-22 |
Bayer Ag |
Neue Kombination zur Behandlung von sexueller Dysfunktion
|
|
IL148291A0
(en)
|
1999-09-16 |
2002-09-12 |
Tanabe Seiyaku Co |
Aromatic nitrogen-containing 6-membered cyclic compounds
|
|
US6436944B1
(en)
|
1999-09-30 |
2002-08-20 |
Pfizer Inc. |
Combination effective for the treatment of impotence
|
|
EA200200240A1
(ru)
*
|
1999-10-11 |
2002-10-31 |
Пфайзер Инк. |
5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
|
|
TWI265925B
(en)
|
1999-10-11 |
2006-11-11 |
Pfizer |
Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
|
|
US20040254153A1
(en)
*
|
1999-11-08 |
2004-12-16 |
Pfizer Inc |
Compounds for the treatment of female sexual dysfunction
|
|
JP2003519150A
(ja)
|
1999-12-24 |
2003-06-17 |
バイエル アクチェンゲゼルシャフト |
新規なイミダゾ［１，３，５］トリアジノン類及びその使用
|
|
KR100358083B1
(ko)
*
|
2000-02-17 |
2002-10-25 |
에스케이케미칼주식회사 |
피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
|
|
DE10010067A1
(de)
|
2000-03-02 |
2001-09-06 |
Bayer Ag |
Neue Imidazotriazinone und ihre Verwendung
|
|
GB0008694D0
(en)
*
|
2000-04-07 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
|
US7019136B2
(en)
|
2000-04-07 |
2006-03-28 |
Novartis, Ag |
8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
|
|
DE10017947A1
(de)
*
|
2000-04-11 |
2001-10-25 |
Merck Patent Gmbh |
Verfahren zur Herstellung benzo-annelierter Heterocyclen
|
|
US7273868B2
(en)
|
2000-04-28 |
2007-09-25 |
Tanabe Seiyaku Co., Ltd. |
Pyrazine derivatives
|
|
CN1440393A
(zh)
|
2000-04-28 |
2003-09-03 |
田边制药株式会社 |
环状化合物
|
|
AU2000254308A1
(en)
*
|
2000-05-17 |
2001-11-26 |
Sk Chemicals Co., Ltd. |
Pyrazolopyrimidinone derivatives, process for their preparation and their use
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
UA74826C2
(en)
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
US6730786B2
(en)
*
|
2000-06-22 |
2004-05-04 |
Pfizer Inc |
Process for the preparation of pyrazolopyrimidinones
|
|
US6667398B2
(en)
|
2000-06-22 |
2003-12-23 |
Pfizer Inc |
Process for the preparation of pyrazolopyrimidinones
|
|
DE10031585A1
(de)
|
2000-06-29 |
2002-01-10 |
Merck Patent Gmbh |
2-Aminoalkyl-thieno[2,3-d]pyrimidine
|
|
DE10031584A1
(de)
|
2000-06-29 |
2002-01-10 |
Merck Patent Gmbh |
5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
|
|
AU2001276403A1
(en)
*
|
2000-07-12 |
2002-01-21 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Use of inhibitors to multidrug resistance protein 5 (mrp5) to enhance intracellular levels of cyclic nucleotides
|
|
BRPI0003386B8
(pt)
*
|
2000-08-08 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
|
|
PE20020394A1
(es)
|
2000-08-18 |
2002-06-21 |
Agouron Pharma |
Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
|
|
AU2000267375A1
(en)
*
|
2000-08-23 |
2002-03-04 |
Lg Life Sciences Ltd. |
Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
|
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
ES2381862T3
(es)
|
2000-09-06 |
2012-06-01 |
Mitsubishi Tanabe Pharma Corporation |
Preparaciones para administración por vía oral
|
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
GB0025782D0
(en)
*
|
2000-10-20 |
2000-12-06 |
Pfizer Ltd |
Use of inhibitors
|
|
DE60005024T2
(de)
*
|
2000-10-23 |
2004-06-24 |
The Jordanian Pharmaceutical Manufacturing and Medical Equipment Co. Ltd. |
Verwendung von Sulfadiazin und Sulfadimidine zur Behandlung der erektilen Dysfunktion
|
|
DE10063108A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Bayer Ag |
Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
|
|
JP3940290B2
(ja)
*
|
2000-12-22 |
2007-07-04 |
ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド |
新規化合物
|
|
SE0004780D0
(sv)
|
2000-12-22 |
2000-12-22 |
Jordanian Pharmaceutical Mfg & |
Novel compunds
|
|
WO2002062343A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Merck Patent Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
|
|
DE10107639A1
(de)
*
|
2001-02-15 |
2002-08-22 |
Bayer Ag |
2-Alkoxyphenyl-substituierte Imidazotriazinone
|
|
JP4179784B2
(ja)
|
2001-02-15 |
2008-11-12 |
田辺三菱製薬株式会社 |
口腔内速崩壊性錠
|
|
EP1364950A4
(en)
|
2001-02-26 |
2005-03-09 |
Tanabe Seiyaku Co |
Pyridopyrimidine and naphthyridine derivatives
|
|
US6784185B2
(en)
|
2001-03-16 |
2004-08-31 |
Pfizer Inc. |
Pharmaceutically active compounds
|
|
MXPA03006310A
(es)
*
|
2001-03-16 |
2003-09-16 |
Pfizer |
Compuestos farmaceuticamente activos.
|
|
WO2004028341A2
(en)
*
|
2001-03-19 |
2004-04-08 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke; methods of treatment
|
|
US20040014099A1
(en)
*
|
2001-03-19 |
2004-01-22 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke; methods of treatment
|
|
US20030054531A1
(en)
*
|
2001-03-19 |
2003-03-20 |
Decode Genetics Ehf, |
Human stroke gene
|
|
US20050164220A1
(en)
*
|
2001-03-19 |
2005-07-28 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke: method of treatment
|
|
US6794387B2
(en)
|
2001-03-28 |
2004-09-21 |
Pfizer Inc. |
Pharmaceutically active compounds
|
|
GB0107751D0
(en)
*
|
2001-03-28 |
2001-05-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
DE10118306A1
(de)
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
|
|
WO2002083631A1
(en)
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
KR100393160B1
(ko)
*
|
2001-06-14 |
2003-07-31 |
한국과학기술연구원 |
신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
|
|
WO2002102385A1
(en)
*
|
2001-06-14 |
2002-12-27 |
Sampad Bhattacharya |
Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
|
|
CN1127506C
(zh)
*
|
2001-06-29 |
2003-11-12 |
刘宝顺 |
一种治疗阳痿的新化合物
|
|
DE10135815A1
(de)
|
2001-07-23 |
2003-02-06 |
Bayer Ag |
Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
|
|
EP1790652A1
(en)
*
|
2001-08-28 |
2007-05-30 |
Schering Corporation |
Polycyclic guanine phosphodiesterase V inhibitors
|
|
EP1421084B1
(en)
|
2001-08-28 |
2008-05-14 |
Schering Corporation |
Polycyclic guanine phosphodiesterase v inhibitors
|
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
|
WO2003042216A1
(en)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
|
ATE375347T1
(de)
*
|
2001-12-13 |
2007-10-15 |
Asubio Pharma Co Ltd |
Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
|
|
US7645878B2
(en)
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
AR040233A1
(es)
*
|
2002-05-31 |
2005-03-23 |
Schering Corp |
Polimorfos inhibidores de xantina fosfodiesterasa v
|
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
|
CA2490239C
(en)
|
2002-06-19 |
2011-05-24 |
Janssen Pharmaceutica N.V. |
Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
|
|
DE10232113A1
(de)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
|
WO2004072079A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Pfizer Limited |
Hydrated and anhydrous sildenafil hemi-citrate compound
|
|
DE10325813B4
(de)
|
2003-06-06 |
2007-12-20 |
Universitätsklinikum Freiburg |
Prophylaxe und/oder Therapie bei der portalen Hypertonie
|
|
CN100374441C
(zh)
|
2003-06-06 |
2008-03-12 |
天津倍方科技发展有限公司 |
二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
|
|
PL1644021T3
(pl)
|
2003-06-13 |
2013-01-31 |
Ironwood Pharmaceuticals Inc |
Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
|
|
CN1867353A
(zh)
*
|
2003-10-13 |
2006-11-22 |
迈克尔·杰米克 |
Lh用于在女性受试者中产生性欲和达到性高潮的用途
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
WO2005053790A1
(ja)
*
|
2003-12-02 |
2005-06-16 |
Hakuju Institute For Health Science Company, Ltd. |
非薬理的な生殖機能の制御方法及びその装置
|
|
CN100360531C
(zh)
*
|
2003-12-18 |
2008-01-09 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
|
|
US9226909B2
(en)
|
2004-04-19 |
2016-01-05 |
Strategic Science & Technologies, Llc |
Beneficial effects of increasing local blood flow
|
|
CA2563670C
(en)
*
|
2004-04-19 |
2014-09-16 |
Strategic Science & Technologies, Llc |
Transdermal delivery of beneficial substances effected by a hostile biophysical environment
|
|
KR101292492B1
(ko)
|
2004-05-11 |
2013-08-01 |
이모셔널 브레인 비.브이. |
약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
|
|
US7700608B2
(en)
|
2004-08-04 |
2010-04-20 |
Shire Holdings Ag |
Quinazoline derivatives and their use in the treatment of thrombocythemia
|
|
US20060030574A1
(en)
|
2004-08-04 |
2006-02-09 |
Shire Holdings Ag |
Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
|
|
EP1781254A2
(en)
*
|
2004-08-23 |
2007-05-09 |
Mannkind Corporation |
Pulmonary delivery of inhibitors of phosphodiesterase type 5
|
|
CN100347174C
(zh)
*
|
2004-09-10 |
2007-11-07 |
上海特化医药科技有限公司 |
杂环并嘧啶酮衍生物、制备方法和用途
|
|
KR101289917B1
(ko)
|
2004-10-18 |
2013-07-25 |
폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 |
평활근을 이완시키기 위한 활성 성분을 함유하는 리포좀조성물, 이런 조성물의 생산 및 이의 치료적 용도
|
|
DE102005009240A1
(de)
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
|
US20060235005A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Oak Labs, Corp. |
Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
|
|
UA84688C2
(uk)
*
|
2005-04-15 |
2008-11-25 |
Виктор Павлович Кутняк |
Засіб для лікування еректильної дисфункції
|
|
RU2336878C2
(ru)
*
|
2005-05-16 |
2008-10-27 |
Виктор Павлович Кутняк |
Средство для лечения эректильной дисфункции
|
|
AU2006282896A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
US20090186896A1
(en)
*
|
2005-09-29 |
2009-07-23 |
Bayer Healthcare Ag |
PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
JP2009513672A
(ja)
|
2005-10-31 |
2009-04-02 |
ブレインセルス，インコーポレイティド |
神経発生のｇａｂａ受容体媒介調節
|
|
US20070225217A1
(en)
|
2005-11-09 |
2007-09-27 |
Combinatorx, Incorporated |
Methods, compositions, and kits for the treatment of medical conditions
|
|
EP1790343A1
(en)
|
2005-11-11 |
2007-05-30 |
Emotional Brain B.V. |
Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
|
|
CN1966506A
(zh)
|
2005-11-17 |
2007-05-23 |
上海特化医药科技有限公司 |
吡唑并嘧啶酮衍生物及其制备方法和用途
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
WO2007124045A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Ampla Pharmaceuticals, Inc. |
Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
|
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
KR101390579B1
(ko)
*
|
2006-05-15 |
2014-05-19 |
유나이티드 세러퓨틱스 코오포레이션 |
정량 흡입기를 사용한 트레프로스티닐 투여
|
|
US7998971B2
(en)
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
DE102006043443A1
(de)
|
2006-09-15 |
2008-03-27 |
Bayer Healthcare Ag |
Neue aza-bicyclische Verbindungen und ihre Verwendung
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP1925307A1
(en)
|
2006-11-03 |
2008-05-28 |
Emotional Brain B.V. |
Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
|
|
US7910597B2
(en)
|
2006-11-28 |
2011-03-22 |
Shire Llc |
Substituted quinazolines
|
|
CN101563348B
(zh)
|
2006-12-21 |
2011-08-24 |
上海特化医药科技有限公司 |
西地那非的制备方法及其中间体
|
|
BRPI0807282A2
(pt)
*
|
2007-02-12 |
2014-04-29 |
Dmi Biosciences Inc |
Tratamento de ejaculação precoce e disfunção erétil co-mórbidas
|
|
US20080194529A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Auspex Pharmaceuticals, Inc. |
HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
|
|
SG178775A1
(en)
*
|
2007-02-12 |
2012-03-29 |
Dmi Biosciences Inc |
Reducing side effects of tramadol
|
|
ES2310144B1
(es)
|
2007-06-15 |
2010-01-12 |
Galenicum Health, S.L. |
Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
|
|
DE102007028869A1
(de)
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
US20090181975A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
AP3089A
(en)
|
2008-05-02 |
2015-01-31 |
Gilead Sciences Inc |
The use of solid carrier particles to improve the processability of a pharmaceutical agent
|
|
CN102014890B
(zh)
|
2008-05-14 |
2015-08-05 |
思佰益药业股份有限公司 |
男性不育治疗剂
|
|
CN101747282A
(zh)
|
2008-12-10 |
2010-06-23 |
上海特化医药科技有限公司 |
一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
|
|
WO2010067140A1
(es)
|
2008-12-12 |
2010-06-17 |
Siegfried Rhein S.A. De C.V. |
Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
|
|
US20100184722A1
(en)
*
|
2008-12-19 |
2010-07-22 |
Shimoda Biotech (Pty) Ltd |
Inclusion complexes of alpha-cyclodextrin and sildenafil salt
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
RU2391095C1
(ru)
*
|
2009-02-05 |
2010-06-10 |
Закрытое акционерное общество "Березовский фармацевтический завод" |
Фармацевтическая композиция, включающая холина альфосцерат и гопантеновую кислоту (или ее соль), для лечения недостаточности кровообращения мозга и эректильной дисфункции
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
US20100261737A1
(en)
*
|
2009-04-10 |
2010-10-14 |
Medtronic Vascular, Inc. |
Method of Treating Erectile Dysfunction
|
|
WO2010146407A1
(en)
|
2009-06-19 |
2010-12-23 |
Nanoform Hungary Ltd. |
Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
|
|
US12138268B2
(en)
|
2009-06-24 |
2024-11-12 |
Strategic Science & Technologies, Llc |
Treatment of erectile dysfunction and other indications
|
|
US11684624B2
(en)
|
2009-06-24 |
2023-06-27 |
Strategic Science & Technologies, Llc |
Treatment of erectile dysfunction and other indications
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
DE102009035211A1
(de)
|
2009-07-29 |
2011-02-17 |
Ratiopharm Gmbh |
Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
|
|
WO2011051928A1
(en)
|
2009-10-30 |
2011-05-05 |
Medispec Ltd |
Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
KR101861981B1
(ko)
|
2009-11-27 |
2018-05-28 |
아드베리오 파마 게엠베하 |
제약상 물질로서 사용하기 위한 메틸-(4,6-디아미노-2-(1-(2-플루오로벤질)-1ｈ-피라졸로(3,4-ｂ)피리디노-3-일)피리미디노-5-일)메틸카르바메이트의 제조 방법 및 그의 정제
|
|
EP2517705B1
(en)
|
2009-12-21 |
2016-10-19 |
Acef S/A |
Cubebin as vasodilating agent in the therapy of erectile dysfunction
|
|
CU24162B1
(es)
|
2010-02-27 |
2016-03-31 |
Bayer Ip Gmbh |
Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
|
|
EP3108888B1
(en)
|
2010-03-15 |
2020-02-12 |
United Therapeutics Corporation |
Treatment for pulmonary hypertension
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
WO2012000634A1
(de)
|
2010-06-29 |
2012-01-05 |
Georg Bambach |
Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
|
|
CN101891747B
(zh)
*
|
2010-07-02 |
2012-04-25 |
张南 |
抑制5型磷酸二酯酶的化合物及制备方法
|
|
TW201210584A
(en)
|
2010-08-18 |
2012-03-16 |
Alcon Res Ltd |
Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
|
|
DE102010040187A1
(de)
|
2010-09-02 |
2012-03-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
|
|
DE102010040924A1
(de)
|
2010-09-16 |
2012-03-22 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
|
|
EP2658551B1
(en)
|
2010-12-29 |
2020-07-01 |
Strategic Science & Technologies, LLC |
Treatment of erectile dysfunction and other indications
|
|
KR101521861B1
(ko)
|
2011-02-02 |
2015-05-21 |
노파르티스 아게 |
Ａｌｋ 억제제의 사용 방법
|
|
CA2841748C
(en)
|
2011-07-15 |
2021-06-15 |
Nusirt Sciences, Inc. |
Compositions and methods for modulating metabolic pathways
|
|
AT512084A1
(de)
|
2011-10-20 |
2013-05-15 |
Univ Wien Tech |
Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
|
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
CA2864322C
(en)
|
2012-02-28 |
2016-08-09 |
Seoul Pharma. Co., Ltd. |
High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
|
|
US9198454B2
(en)
|
2012-03-08 |
2015-12-01 |
Nusirt Sciences, Inc. |
Compositions, methods, and kits for regulating energy metabolism
|
|
CN104918610B
(zh)
|
2012-11-13 |
2018-04-10 |
纽斯尔特科学公司 |
用于增强能量代谢的组合物和方法
|
|
JP6120985B2
(ja)
|
2012-12-04 |
2017-04-26 |
アリビオ， インコーポレーテッド |
ホスホジエステラーゼタイプ５活性阻害剤を含む神経細胞のアポトーシス抑制用組成物
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
AU2014220801A1
(en)
|
2013-02-21 |
2015-09-10 |
Adverio Pharma Gmbh |
Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
|
|
JP6550370B2
(ja)
|
2013-03-15 |
2019-07-24 |
ニューサート サイエンシーズ， インコーポレイテッド |
脂質レベルを低下させるロイシンおよびニコチン酸
|
|
AU2015222754B2
(en)
|
2014-02-27 |
2020-06-25 |
Nusirt Sciences Inc. |
Compositions and methods for the reduction or prevention of hepatic steatosis
|
|
SG11201703199UA
(en)
|
2014-11-03 |
2017-05-30 |
Bayer Pharma AG |
Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
CN104650093B
(zh)
*
|
2015-02-02 |
2017-01-25 |
王靖林 |
一种西地那非类似物的合成方法
|
|
WO2017168174A1
(en)
|
2016-04-02 |
2017-10-05 |
N4 Pharma Uk Limited |
New pharmaceutical forms of sildenafil
|
|
US9988367B2
(en)
|
2016-05-03 |
2018-06-05 |
Bayer Pharma Aktiengesellschaft |
Amide-substituted pyridinyltriazole derivatives and uses thereof
|
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
US10568847B2
(en)
*
|
2016-12-13 |
2020-02-25 |
James J. Caprio |
Compositions and methods for treatment of erectile dysfunction
|
|
WO2018134848A1
(en)
|
2017-01-20 |
2018-07-26 |
Laila Nutraceuticals |
Dietary supplements for inhibiting pde5 and increasing cgmp levels
|
|
SG11201912429RA
(en)
|
2017-06-21 |
2020-01-30 |
Transgene Sa |
Personalized vaccine
|
|
EP3650444B8
(en)
*
|
2017-07-07 |
2023-10-18 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
|
|
JP2021516957A
(ja)
|
2018-03-07 |
2021-07-15 |
トランジェーヌＴｒａｎｓｇｅｎｅ |
パラポックスウイルスベクター
|
|
CA3103695A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
|
WO2019241588A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
|
SE542968C2
(en)
|
2018-10-26 |
2020-09-22 |
Lindahl Anders |
Treatment of osteoarthritis
|
|
BR112021012630A2
(pt)
|
2018-12-28 |
2022-12-13 |
Transgene Sa |
Poxvírus modificado, método para produzir o poxvírus modificado e composição
|
|
CN113493459B
(zh)
*
|
2020-04-07 |
2022-12-13 |
广州白云山医药集团股份有限公司白云山制药总厂 |
Pde5抑制剂化合物及其制备方法和应用
|
|
CN111732593A
(zh)
*
|
2020-07-07 |
2020-10-02 |
黄泳华 |
哌嗪氧化物衍生物及其组合物、制备方法与用途
|
|
CN115785101B
(zh)
*
|
2022-11-23 |
2023-10-13 |
西安市食品药品检验所 |
一种含有苯基哌嗪结构的那非类化合物及其制备方法
|
|
EP4656194A1
(en)
|
2023-01-25 |
2025-12-03 |
Aribio Co., Ltd |
Composition for preventing or treating post-traumatic stress disorder, comprising phosphodiesterase type 5 inhibitor as active ingredient
|